scholarly journals 18F FDG PET-CT for EBRT Planning in Inoperable Rectal Carcinoma after Receiving Chemotherapy– A

2018 ◽  
Vol 19 (1) ◽  
pp. 56
Author(s):  
Shamim MF Begum ◽  
Fatima Begum ◽  
Raihan Hossain ◽  
Md Abu Bakker Siddique ◽  
Khokon Kumar Nath ◽  
...  

<p><span><span style="font-size: medium;">Colorectal cancer (CRC) is the third most commonly diagnosed cancer in men and the second in women globally. The incidence varies with geographic difference. In Bangladesh, hospital based cancer registry shows rate of CRC in male 10.1%- 12% and in female 3% - 12.0%. The prognosis of the disease and treatment planning depends upon the staging of the disease. Surgery is usually a common way of treatment of rectal cancer except some cases with advanced stage. Radiation therapy, often with chemotherapy, is frequently used in the adjuvant or neoadjuvant setting for the treatment of rectal cancers. External beam radiation therapy (EBRT) is a well practiced method of treatment in the in-operable cases of rectal cancer. 18F FDG PET-CT is a well recognized imaging tool in the pretreatment evaluation of colorectal cancer worldwide. Accurate staging is needed for proper selection of treatment and cost effectiveness. Here, we discussed a case of rectal cancer (stage IV) with post chemotherapy state with history of palliative loop iliostomy bypass. The patient was referred for 18 F FDG PET-CT scan for restaging of the disease and to localize functioning tumor site for external beam radiotherapy (EBRT) planning. FDG PET-CT imaging revealed FDG avidity at the primary tumor site, perircetal fat and multiple FDG avid hypermetabolic lymphnodes in pelvic cavity. A focal FDG avid lesion in anterior aspect of liver suggests hepatic involvement. The fusion PET-CT imaging has played an important role in the further management of the patient by providing guidelines in EBRT.</span></span></p><p><span><span style="font-size: medium;">Bangladesh J. Nuclear Med. 19(1): 56-60, January 2016</span></span></p>

Author(s):  
Judit A. Adam ◽  
Hester Arkies ◽  
Karel Hinnen ◽  
Lukas J. Stalpers ◽  
Jan H. van Waesberghe ◽  
...  

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Riccardo Caruso ◽  
Emilio Vicente ◽  
Yolanda Quijano ◽  
Hipolito Duran ◽  
Isabel Fabra ◽  
...  

Abstract Objectives Neoadjuvant chemoradiation (nCRT) is universally considered to be a valid treatment to achieve downstaging, to improve local disease control and to obtain better resectability in locally advanced rectal cancer (LARC). The aim of this study is to correlate the change in the tumour 18F-FDG PET-CT standardized uptake value (SUV) before and after nCRT, in order to obtain an early prediction of the pathologic response (pR) achieved in patients with LARC. Data description We performed a retrospective analysis of patients with LARC diagnosis who underwent curative resection. All patients underwent a baseline 18F-FDG PET-CT scan within the week prior to the initiation of the treatment (PET-CT SUV1) and a second scan (PET-CT SUV2) within 6 weeks of the completion of nCRT. We evaluated the prognostic value of 18F-FDG PET-CT in terms of disease-free survival (DFS) and overall survival (OS) in patients with LARC.A total of 133 patients with LARC were included in the study. Patients were divided in two groups according to the TRG (tumour regression grade): 107 (80%) as the responders group (TRG0-TRG1) and 26 (25%) as the no-responders group (TRG2-TRG3). We obtained a significant difference in Δ%SUV between the two different groups; responders versus no-responders (p < 0.012). The results of this analysis show that 18F-FDG PET-CT may be an indicator to evaluate the pR to nCRT in patients with LARC. The decrease in 18F-FDG PET-CT uptake in the primary tumour may offer important information in order for an early identification of those patients more likely to obtain a pCR to nCRT and to predict those who are unlikely to significantly regress.


2016 ◽  
Vol 27 (suppl_9) ◽  
Author(s):  
S.H. Lee ◽  
K.C. Lee ◽  
K. Sung ◽  
E.Y. Choi ◽  
J.B. Bae ◽  
...  

2021 ◽  
Author(s):  
Riccardo Caruso ◽  
Emilio Vicente ◽  
Yolanda Quijano ◽  
Hipolito Duran ◽  
Isabel Fabra ◽  
...  

Abstract Objectives: Neoadjuvant radiochemotherapy (nCRT) is universally considered to be a valid treatment to achieve downstaging, improve local disease control and obtain better resectability in locally advanced rectal cancer (LARC). The aim of this study is to correlate the change in tumor 18F -FDG PET-CT standardized uptake value (SUV) before and after nCRT, in order to obtain an early prediction of pathologic response (pR) achieved in patients with LARC.Data description: We performed a retrospective analysis of patients with LARC diagnosis who underwent curative resection. All patients received nCRT and surgical treatment was carried after 8/12th. All patients underwent a baseline 18F -FDG PET-CT scan within the week prior to the initiation of the treatment (PET-CT SUV1) and a second scan (PET-C T SUV2) within six weeks of the completion of nCRT. Furthermore, we evaluated the prognostic value of 18F -FDG PET-CT in terms of disease free survival (DFS) and overall survival (OS) in patients with LARC.A total of 133 patients with LARC were included in the study. Patients were divided in two groups according to the TRG (tumor regression grade): 107 (80%) as Responders group (TRG0-TRG1) and 26 (25%) as the No-Responders group (TRG2-TRG3). We obtained a significant difference in Δ%SUV between the two different groups responders vs no responders (p<0.012).The results of this analysis have shown that 18F-FDG PET-CT may be an indicator in order to evaluate the pR to nCRT in patients with LARC. The decrease in 18F-FDG PET-CT uptake in the primary tumor may offer primary information in order to early identify those patients more likely to obtain a pCR to nCRT and predict those unlikely to regress significantly.


Sign in / Sign up

Export Citation Format

Share Document